Sunil Healthcare Ltd

As of November 7, 2025, Sunil Healthcare is considered overvalued with a PE Ratio of 44.63 and an EV to EBITDA of 11.04, lagging behind peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -3.46%.

As of November 7, 2025, Sunil Healthcare is fairly valued with a PE ratio of 44.63, higher than Sun Pharma but lower than Divi's Laboratories, and has underperformed the Sensex over the past year, indicating it may not be the best value in its sector.

As of November 7, 2025, Sunil Healthcare is fairly valued with a PE ratio of 44.63, showing short-term resilience with a 1-week return of 4.58%, but has underperformed over the past year with a return of -11.93% compared to the Sensex's 4.62%.

Sunil Healthcare's latest results show a return to profitability with a net profit of ₹0.91 crores and improved operating margins, but challenges remain due to low return ratios and high debt levels, raising concerns about long-term sustainability.

Sunil Healthcare's historical performance shows a decline in net sales and profits, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit after tax turning negative from 6.68 Cr to -1.42 Cr. However, cash flow from operating activities improved from 7.00 Cr to 11.00 Cr during the same period.

As of 03-Nov, Sunil Healthcare Ltd's stock price is Rs 75.00, up 4.17% today but down 8.87% over the past month and 14.82% year-over-year. Despite today's gains, the stock's year-to-date performance is negative at -3.85%, indicating struggles relative to the broader market.

As of 27-Oct, Sunil Healthcare Ltd is priced at 72.00, showing a slight increase but trading below key moving averages, indicating a downward trend. Despite a significant profit increase, the stock faces long-term fundamental weaknesses and has underperformed compared to market benchmarks.

As of 17-Oct, Sunil Healthcare Ltd's stock price is at 73.25, down 1.8% and has underperformed significantly with a -15.33% return over the past year. The stock is trading below key moving averages, indicating a bearish trend, and faces challenges due to weak fundamentals and high debt levels.

Sunil Healthcare has experienced a declining trend in net sales and profitability, with net sales dropping from 119.16 Cr in Mar'22 to 83.42 Cr in Mar'25. Despite improved operating profit and cash flow, the company reported negative profits before and after tax in Mar'25.

Sunil Healthcare has experienced a declining trend in net sales and profitability, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit before tax turning negative at -1.22 Cr in Mar'25. Despite increasing total assets, the company's liabilities also rose significantly during this period.

As of 25-Sep, Sunil Healthcare Ltd's stock price is at 81.00, down 2.41%, and has underperformed its sector today. Despite a recent monthly gain of 7.86%, the stock has declined 11.96% over the past year and shows a significant long-term drop of 39.66% over three years.

Sunil Healthcare has experienced a declining trend in net sales and profitability, with net sales dropping from 119.16 Cr in Mar'22 to 83.42 Cr in Mar'25 and a reported net loss of -1.42 Cr in Mar'25. Despite a positive cash flow from operating activities of 11.00 Cr in Mar'25, the company faces increasing liabilities and ongoing financial challenges.

Sunil Healthcare has experienced a declining trend in net sales and profitability, with net sales dropping from 119.16 Cr in Mar'22 to 83.42 Cr in Mar'25, and a loss of 1.42 Cr in profit after tax for the same period. Additionally, total liabilities increased significantly, and cash flow from operating activities turned negative in Mar'24.